Document:

EX-10.1

 Exhibit 10.1 

 
 

 
 EXECUTION COPY 
 April 9, 2013 
 Purdue Pharma L.P. 
 One Stamford Forum 
 201 Tresser Blvd. 
 Stamford, Connecticut 06901 
 Beacon Company 

c/o Jonathan G. White, Esq. 
 Ogier House

 The Esplanade 
 St. Helier, Jersey
JE4 9WG 
 Channel Islands 
 Rosebay
Medical Company L.P. 
 c/o North Bay Associates 
 14000 Quail Springs Parkway 
 Oklahoma City, Oklahoma 73134 

 

	Re:	Lock-Up Release & Registration Rights Waiver 

 Ladies and Gentlemen: 
 This letter agreement (this
“Agreement”) confirms the agreement among Infinity Pharmaceuticals, Inc., a Delaware corporation (the “Company”), Purdue Pharma L.P. (“Purdue”), Beacon Company
(“Beacon”) and Rosebay Medical Company L.P. (“Rosebay” and, together with Purdue and Beacon, the “BRP Entities”) regarding certain matters related to the Securities Purchase
Agreement dated as of July 17, 2012, among the Company and the BRP Entities (the “Purchase Agreement”), as set forth in greater detail below. Defined terms used herein but not otherwise defined herein shall have the
meaning given to them in the Purchase Agreement. 
  

	1.	Background. In connection with the offering of shares of the Company’s common stock, par value $0.001 (the “Common Stock”) priced on
December 13, 2012, pursuant to Registration Statement No. 333-184775 on Form S-3 (the “Offering”), the BRP Entities are restricted from, among other things, selling or otherwise transferring, directly or indirectly,
shares of the Common Stock for a period of 180 days subsequent to the Offering, or June 12, 2013 pursuant to Section 4.7 of the Purchase Agreement (the “PA Transfer Restriction”) and the lock-up agreements executed
by each of the BRP Entities in favor of Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC (the “Underwriters”) dated December 10, 2012 (the “Lock-Up Agreements”). Beacon and Rosebay
(collectively, the “Selling Stockholders”) have requested that the Company permit and facilitate the sale of shares of Common Stock held by the Selling Stockholders that would not otherwise be eligible for sale pursuant to
the restrictions set forth in the foregoing sentence. 

  
 

 

	2.	Proposed Sale. In connection with consummating a one-time firm-commitment underwritten offering of shares of Common Stock currently held by the Selling
Stockholders to be publicly announced in a press release no later than April 10, 2013 (“Press Release”) pursuant to Registration Statement No. 333-184184 on Form S-3 (the “Proposed
Sale”), the Company and the BRP Entities hereby agree to the following, effective as of the issuance of the Press Release announcing the Proposed Sale: 

 

	 	(a)	In the event the Selling Stockholders sell any shares of Common Stock in the Proposed Sale, then: 

 

	 	A.	the BRP Entities agree that they will not exercise any of their rights under Section 4.5 of the Purchase Agreement in connection with the Company’s next
Underwritten Offering, which, for the avoidance of doubt, does not include the Proposed Sale; 

  

	 	B.	the Company waives the PA Transfer Restrictions only to the sale of shares of Common Stock in the Proposed Sale and the BRP Entities shall otherwise remain subject to
all restrictions set forth in Section 4.7 of the Purchase Agreement (as amended below) with respect to any other shares of Common Stock or other applicable securities; and 

 

	 	C.	Section 4.7 of the Purchase Agreement is hereby deleted in its entirety and a new Section 4.7 is inserted in lieu thereof which reads as follows:

 “(a) During the period beginning on the date the BRP Entities sell any Shares in connection with a
firm-commitment underwritten offering of Shares to be publicly announced no later than April 10, 2013 pursuant to Registration Statement No. 333-184184 on Form S-3 (the “Offering”) and through and including the six-month
anniversary following the time at which the underwriting agreement is signed in connection with the Offering (the “Company Lock-Up Period”), the BRP Entities agree, with respect to all of the Shares not sold by the BRP Entities in
the Offering (the “Remaining Shares”), (i) not to offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right
or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any Remaining Shares or (ii) not to enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership
of any Remaining Shares, whether any transaction described in clause (i) or (ii) above is to be settled by delivery of securities, in cash or otherwise, during the Company Lock-Up Period; provided, however, that the foregoing
restrictions shall not apply to (a) transfers as a bona fide gift, (b) distributions to Associated Companies, (c) transfers by will, other testamentary document or intestate succession to the legal representative, heir, beneficiary or
a member of the immediate family of an Associated Company, (d) the establishment of a trading plan pursuant to Rule 10b5-1 under the Exchange Act, provided that such plan does not provide for the

  
 2 

 
transfer during the Company Lock-Up Period and no public announcement or filing under the Exchange Act regarding the establishment of such plan shall be required of or voluntarily made by or on
behalf of the undersigned or the Company, or (e) sales to an underwriter pursuant to an Underwriting Offering (provided that the BRP Entities are then entitled to exercise their rights under Section 4.5(a) hereof); provided that in
the case of any transfer or distribution pursuant to clause (a), (b), or (c) above, (y) each donee or distributee shall sign and deliver a legally binding written instrument evidencing the donee’s or distributee’s intention
to be bound by this Section 4.7(a), and (z) no filing under Section 16(a) of the Exchange Act, reporting a reduction in beneficial ownership of shares of Common Stock, shall be required or shall be voluntarily made during the
restricted period referred to in the foregoing sentence. 
 (b) During the period between the date of this Agreement and
December 31, 2013 (the “Underwriter Lock-Up Period”), if requested by the Company and/or any managing underwriters, placement agents or initial purchasers for any offering of capital stock proposed by the Company during the
Underwriter Lock-Up Period, the BRP Entities agree to execute, at the time of such offering, agreements (each a “Lock-Up Agreement”) for any such period as may be requested by the Company, the managing underwriters, the placement
agents or the initial purchasers, as the case may be, provided, that all officers, directors and Affiliates of the Company enter into similar agreements with equivalent terms. The Lock-Up Agreements will require the BRP Entities to agree to
(i) not to offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose
of, directly or indirectly, any Remaining Shares still owned or (ii) not to enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of any Remaining Shares still owned, whether
any transaction described in clause (i) or (ii) above is to be settled by delivery of securities, in cash or otherwise, during the lock-up period under the Lock-Up Agreement; provided, however, that the foregoing restrictions
shall not apply to (a) transfers as a bona fide gift, (b) distributions to Associated Companies, (c) transfers by will, other testamentary document or intestate succession to the legal representative, heir, beneficiary or a member of
the immediate family of an Associated Company, (d) the establishment of a trading plan pursuant to Rule 10b5-1 under the Exchange Act, provided that such plan does not provide for the transfer during the lock-up period under the Lock-Up
Agreement and no public announcement or filing under the Exchange Act regarding the establishment of such plan shall be required of or voluntarily made by or on behalf of the undersigned or the Company, or (e) sales to an underwriter pursuant
to an Underwriting Offering (provided that the BRP 

  
 3 

 
Entities are then entitled to exercise their rights under Section 4.5(a) hereof); provided that in the case of any transfer or distribution pursuant to clause (a), (b), or
(c) above, (y) each donee or distributee shall sign and deliver a Lock-Up Agreement, and (z) no filing under Section 16(a) of the Exchange Act, reporting a reduction in beneficial ownership of shares of Common Stock, shall be
required or shall be voluntarily made during the restricted period referred to in this Section 4.7(b). 
 (c) The Company
may impose stop-transfer instructions with respect to the Remaining Shares in accordance with the terms hereof. 
 (d) Any BRP
Entity receiving any written notice from the Company regarding the Company’s plans to effect an offering shall treat such notice confidentially and shall not disclose such information to any person other than as necessary to exercise its rights
under this Agreement.” 
  

	 	(b)	In the event the Selling Stockholders sell no shares of Common Stock in the Proposed Sale, then Section 2(a) above shall be void and have no effect and the BRP
Entities shall remain subject to all rights and restrictions set forth in the Purchase Agreement prior to the execution of this Agreement, including Sections 4.5 and 4.7 thereof. 

 

	3.	Miscellaneous. This Agreement shall be governed by and construed in accordance with the laws of the State of New York without regard to the conflict of law rules
thereof. This Agreement contains the entire understanding and agreement of the parties hereto with respect to the particular subject matter hereof and supersedes all prior or contemporaneous agreements, understandings or discussions between the
parties regarding such particular subject matter; provided, however, that except as otherwise specifically contemplated hereby, the Purchase Agreement remains in full force and effect as of the date hereof. This Agreement may not be amended or
modified except by a written instrument signed by each of the parties hereto. This Agreement may be executed in multiple counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same instrument.
This Agreement may not be assigned by any party hereto without the prior written consent of the other parties hereto. This Agreement shall be binding upon the parties hereto and their respective successors and permitted assigns.

 [Remainder of Page Intentionally Left Blank] 

  
 4 

 Please confirm the agreement between the Company and BRP Entities to the foregoing by
countersigning this Agreement in the space set forth below. 
  

					
	Very truly yours,
	
	INFINITY PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Lawrence E. Bloch

		 	Name:	 	Lawrence E. Bloch, M.D., J.D.
		 	Title:	 	EVP, Chief Financial Officer and Chief Business Officer

  

					
	Acknowledged and agreed as of the date first set forth above:
	
	PURDUE PHARMA L.P.
		
	By:	 	Purdue Pharma Inc., its general partner
		
	By:	 	 /s/ Stuart Baker

		 	Name:	 	Stuart Baker
		 	Title:	 	Executive Vice President
	
	BEACON COMPANY
		
	By:	 	 /s/ Anthony M. Roncalli

		 	Name:	 	Anthony M. Roncalli
		 	Title:	 	Assistant Secretary
	
	ROSEBAY MEDICAL COMPANY L.P.
		
	By:	 	Rosebay Medical Company, Inc., its general partner
		
	By:	 	 /s/ Anthony M. Roncalli

		 	Name:	 	Anthony M. Roncalli
		 	Title:	 	Vice President

 [Signature Page to Letter Agreement]EX-10.33

 Exhibit 10.33 
 *** Text Omitted and Filed Separately 
 Confidential Treatment Requested

 Under 17 C.F.R. §§ 200.80(b)(4) 
 and 203.406 
 COMMERCIAL LICENSE AGREEMENT 

This Commercial License Agreement (“Commercial License”), effective the 15th day of April, 2010 (“Effective Date”), is made by and
between Cargill, Inc., through its Bio Technology Development Center, having its principal place of business at 15407 McGinty Road West, Wayzata, MN 55391 (hereinafter “Cargill”), and Bioamber S.A.S., having a place of business at Route de
Bazancourt, F-51110, Pomacle France (“Bioamber”). Cargill and Bioamber are referred to herein as “Parties”, in singular or plural usage, as required by context. 
 WHEREAS, Cargill has developed a yeast strain designated CB1 for fermenting glucose and/or sucrose, and/or mixed sugar streams and related research tools for modifying CB1, which are protected by Licensed
Patents (as defined in Section 1.3 below); 
 WHEREAS, Bioamber has engaged Cargill under the Development Agreement, to which this
Commercial License is an Exhibit, to further develop or modify CB1 with the goal of fermenting glucose and/or sucrose, and/or mixed sugar streams to produce succinic acid and salts thereof; 
 WHEREAS, the Parties also desire to enter into this Commercial License concurrently with the Development Agreement for the purpose of Cargill granting and Bioamber acquiring certain rights to
commercialize the CB1 strain, Improvements made under the Development Agreement, and related patent rights for the production of succinic acid and salts thereof as specified in this Commercial License under its terms and conditions; 

NOW, THEREFORE, in consideration of the mutual covenants set forth herein, the Parties agree as follows: 

1. DEFINITIONS 
 1.1 “CB1 Strain”
shall mean Modified CB1 as defined in the Development Agreement between the Parties. 
 1.2 “Confidential Information” shall mean all
information related to this Commercial License in any form disclosed in any manner by or on behalf of one Party to the other Party during the term of this Commercial License. Without limitation, Confidential Information shall include information
about products, raw materials, samples, packaging, manufacturing processes, financial information, research information, tools, business plans, customer lists and supplier lists. 
 1.3 “Licensed Patents” shall mean those patents and patent applications defined in Section 2.5 of the Development Agreement and in Exhibit B thereto provided that those patents and patent
applications listed in Exhibit B under the heading of “Needed only if Bioamber takes the cellulosics option” are only to be included within the term “Licensed Patents” in the event that Bioamber exercises its option under
Section 3 of the Development Agreement. 

  
 Cargill
Confidential 
 - 1 - 
 * Confidential treatment requested 

 1.4 “Know-How” shall mean information developed by Cargill during the Development Agreement and
this Commercial License concerning the use of CB1 Strain for the production of Product. Information relating to the Licensed Tool Kit (as defined in the Development Agreement) and the Licensed Tool Kit itself used to genetically modify CB1 Strain
shall not be included within Know-How. 
 1.5 “Product” shall mean succinic acid and salts thereof produced by use of CB1 Strain to
ferment glucose and/or sucrose, and, in the event that Bioamber exercises its option under Section 3 of the Development Agreement, “Product” shall also mean succinic acid and salts thereof produced by use of CB1 Strain to ferment
cellulosic feedstock. 
 1.6 “Improvements” shall mean those inventions or discoveries that are defined in Section 5.2 of the
Development Agreement, including “Bioamber Improvements”, “Cargill Improvements”, and “Joint Improvements” as those terms are defined in Section 5.2 of the Development Agreement and used in this Commercial License.

 1.7 “Net Sale(s)” shall mean the gross sale or transfer quantity of Succinic Acid Equivalent measured in US pounds that is made by
Bioamber and its sublicensees and sold or otherwise transferred to any third party or to Bioamber itself less allowed Product returns and reasonable Product allowances given by Bioamber and its sublicensees, all as determined by Bioamber’s
standard accounting practices. For purposes of clarity, Product allowances shall not include discounts given to customers in the form of Product credits. 
 1.8 “Quarter” shall mean a three month time period from January 1 to March 31, April 1 to June 30, July 1 to September 30, or October 1 to
December 31 in any year during the term of this Commercial License. 
 1.9 “Succinic Acid Equivalent” means the ratio of the
molecular weight of succinic acid to molecular weight of Product multiplied by the dry weight mass of the Product produced. As an example, in the case were the Product is diammonium succinate (DAS), the Succinic Acid (SA) Equivalent would be
calculated as follows: 1 pound DAS x (118/152) = 0.7763 pound of SA, where 118 is the molecular weight of succinic acid and 152 is the molecular weight of diammonium succinate. 
 1.10 “Affiliates” shall mean any person or entity that directly or indirectly controls, is controlled by, or is under common control with such person or entity, and is identified in writing and
included in Exhibit X, which may be updated periodically as mutually agreed by the Parties. For purposes of the preceding sentence, “control” means the right to control, or actual control of, the management of such other entity, whether by
ownership of securities, by voting rights, by agreement or otherwise. Neither Party’s Affiliates are included under the rights and obligations of the provisions of this Commercial License unless done so by an explicit reference. 

1.11 As used throughout this Commercial License, (i) “sublicense” shall mean any agreement between Bioamber and a third party (including
Affiliates) granting the third party commercial rights under or to any CB1 Strain, Licensed Patents, Know-How and/or Improvements, and (ii) “sublicensee” shall mean any such third party entering into such sublicense with Bioamber.

  
 Cargill
Confidential 
 - 2 - 
 * Confidential treatment requested 

 2. CB1 STRAIN DEVELOPMENT AND REGULATORY APPROVAL 
 2.1 The Parties will attempt to develop CB1 Strain under the terms of the Development Agreement for the purpose of the commercialization of the Product. 

2.2 Bioamber agrees to use its best efforts to obtain the regulatory approvals necessary to make and sell, or otherwise transfer, Products throughout the
world. 
 3. CONFIDENTIAL INFORMATION,AND TRANSFER AND USE OF STRAINS 
 3.1 Both Parties agree that Confidential Information under this Commercial License is subject to the terms and conditions governing “Confidential Information” under Section 4 of the
Development Agreement, including the exclusions therein. Notwithstanding the foregoing, Bioamber shall be permitted to disclose Confidential Information to its shareholders (DNP Green Technology, Inc. and Agro-Industrie Recherches &
Développements, S.A.) and to its sublicensees or potential sublicensees who are bound by an executed confidentiality agreement with terms equivalent to those in the Development Agreement, subject to the requirements for biological materials
specified in Section 3.2 below. 
 3.2 Bioamber shall not transfer or provide any CB1 Strain, or related biological materials, or
biological materials derived from CB1 Strain to any third party, including Affiliates, unless (i) there is a written material transfer agreement in place with such third party that strictly limits such third party to non-commercial evaluation
or testing of such strains or material and prohibits such third party from providing the strain or material to any other party, (ii) there is a written sub-license agreement in place under this Commercial License with such third party as
provided under Section 4.2; and (iii) such third party is obligated not to file patent applications utilizing any data or results learned or obtained while evaluating CB1 Strain. In no event will Bioamber transfer the Licensed Tool Kit to
any third party, except as provided in Section 2.5 of the Development Agreement. 
 3.3 Upon termination of this Commercial License for any
reason (including the end of its term), Bioamber shall destroy and have its sublicensees destroy any and all CB1 Strain and any other biological materials relating to this Commercial License in their possession, and Bioamber shall certify such
destruction in writing to Cargill, except with regard to sublicensees as provided in Section 4.3 of this Commercial License. 
 3.4
Bioamber shall have the first right to enforce the terms in the Sublicense Agreement with respect to the use and custody of the CB1 Strain. In the event Bioamber fails to enforce such provisions in the Sublicense Agreement within a reasonable period
of time, Cargill shall have the right to step in as a named party and enforce such provisions, and Bioamber shall provide assistance thereto. 

  
 Cargill
Confidential 
 - 3 - 
 * Confidential treatment requested 

 3.5 Notwithstanding any other provision of this Commercial License, Bioamber shall use all reasonable
efforts to ensure that no samples of the CB1 Strain are taken from its facilities, (i) Bioamber shall use the CB1 Strain only for the production of Product within the scope of the rights it is granted under Section 4 of this Commercial
License, subject to the limitations specified in that section, (ii) Bioamber shall not reverse engineer, analyze, attempt to analyze, or have analyzed the physical or genetic structure of the CB1 Strain, and (iii) Bioamber shall not modify
the CB1 Strain in any way or use it to develop other biological materials for any purpose whatsoever. Bioamber shall require its sublicensees to comply with the provisions set forth in this Section 3.5. 

4. GRANTS TO BIOAMBER AND CARGILL, AND CARGILL OPTION 
 4.1 Subject to the terms and conditions of this Commercial License, Cargill hereby grants to Bioamber an exclusive, worldwide, royalty bearing license with a limited right to sublicense, subject to
Section 4.2, under and to Licensed Patents, the CB1 Strain, the Know-How, Cargill Improvements, and Joint Improvements to make, have made, use, sell or otherwise transfer, offer for sale, export, and/or import the Product only. 

4.2 Bioamber’s license under Section 4.1 and ownership rights under the Development Agreement include the right to grant sublicenses according
to the following requirements: 
 a. Bioamber will be responsible for reporting on and paying all royalties that are due to
Cargill in accordance with Section 5 of this Commercial License for Product sold or otherwise transferred by any of Bioamber’s sublicensees. 
 b. Any sublicenses granted by Bioamber under this Section 4.2 shall be in writing (“Sublicense Agreement”) and, prior to Bioamber granting any sublicenses to third parties, Cargill shall
have the right to review and approve such Sublicense Agreement that will be used as a template for the sublicensing of the CB1 Strain. Any sublicenses granted by Bioamber under this Section 4.2 shall be subject to the terms and conditions of
this Commercial License, including but not limited to the obligations on Bioamber concerning confidentiality and material transfer provisions as set forth in Section 3. Sublicenses shall not be granted in the geographies listed in Exhibit Y
without the prior written approval of Cargill, such approval not being unreasonably withheld. In considering whether or not to grant sublicenses to third parties in the geographies listed in Exhibit Y, the Parties recognize that it is in their
mutual interest to protect the CB1 Strain, Cargill Confidential Information, Know-How, Improvements, and Licensed Patents under license to Bioamber, and that the geographies listed in Exhibit Y have weaknesses in the legal systems protecting
intellectual property. As such, the Parties agree to undertake joint evaluations of any licensing opportunity in these prohibited geographies, including, for example and without limitation, a risk assessment of the companies or consortiums envisaged
as sublicensees and whether or not such sublicensees are acting under similar guiding principles as Cargill (a copy of Cargill’s Guiding Principles and Compliance Policy on Intellectual Property is attached as Exhibit Z), and that sublicenses
shall not be granted in circumstances where Cargill’s intellectual property is at an unacceptable risk and/or where Cargill withholds its approval based on the joint evaluations of such licensing opportunity in the prohibited geographies.
Further, Bioamber shall inform Cargill in writing prior to entering into confidential discussions with [***] as potential sublicensees of CB1 Strain, Cargill Confidential Information, Know-How, Improvements, and/or Licensed Patents.”

  
 Cargill
Confidential 
 - 4 - 
 * Confidential treatment requested 

 c. No sublicensee under this Commercial License may grant any third party or any Affiliate
of the sublicensee any rights in, any access to, or any copies or samples of the Licensed Patents, the CB1 Strain (and any related biological materials and biological materials derived from CB1 Strain), the Know-How, Cargill Improvements, Joint
Improvements, and Confidential Information for any purpose. 
 d. Any non-remedied breach by a sublicensee of the terms of its
sublicense or the requirements of this Commercial License shall not be considered to be a breach by Bioamber of this Commercial License. 
 e. Only the final commercial strains of CB1, which are adapted for commercially manufacturing Product will be provided to sublicensees. Additionally, Know-How may be provided to sublicensees, but in no
event will the Licensed Tool Kit and pre-commercial CB1 strains be provided to sublicensees. 
 4.3 Effective on the date this Commercial
License is terminated for any reason, prior to the end of its term (the “Termination Date”), and provided that any Bioamber sublicensee is not then in default under the terms of the sublicense to which it is a party, then Bioamber hereby
assigns to Cargill those of its rights, title and interest under any such sublicense that are in effect on the Termination Date that relate to the license granted herein, including the right to receive the portion of the income from the sublicense
that relates to the license provided herein, and Cargill undertakes to respect the terms of any such sublicense as though Cargill itself had contracted directly with such sublicensee, in accordance with the terms of any such sublicense so long as
any such sublicensee respects the terms of its sublicense. 
 4.4 At any time up until the fifth anniversary of the completion of Milestone 3 as
referenced in Section 2.3 of the Development Agreement and described in Exhibit A to the Development Agreement, Cargill shall have the options to purchase (i) a non-exclusive, royalty bearing license to make, have made, use, sell or otherwise
transfer, offer for sale, export, and/or import succinic acid and salts thereof, including the Product under the rights granted to Bioamber under Section 4.1 and under Bioamber’s rights to Bioamber Improvements that are specified in the
Development Agreement, and/or (ii) a non-exclusive royalty bearing license to make, have made, use, sell or otherwise transfer, offer for sale, export, and/or import succinic acid and salts thereof produced by use of Bioamber’s proprietary
E. coli or other strain to ferment glucose and/or sucrose and/or cellulosic feedstock (in the case of this option (ii), such license shall be to and under any and all proprietary and intellectual property rights that are possessed or
controlled by Bioamber respecting the relevant E. coli or other strain and the process and technology related to its use for the licensed purpose; such license shall include provisions to convey the strain, process and technology to Cargill
as necessary for it to practice its license). In the event Cargill exercises either or both of these options, Cargill shall be [***]. The licensing by Cargill of the Bioamber technology to produce the Product, including but not limited to the strain
and the downstream processing, shall be for a single plant on a single site, and shall be consistent with the standard practices and deal structure of Bioamber’s licensing program. Cargill shall have the right to purchase additional licenses to
build additional plants, consistent with the principles described in this Section 4.4. 

  
 Cargill
Confidential 
 - 5 - 
 * Confidential treatment requested 

 4.5 Bioamber hereby grants to Cargill anexclusive, worldwide, royalty-free license with an unlimited right
to sublicense under and to Bioamber Improvements to make, have made, use, sell or otherwise transfer, offer for sale, export, and/or import any and all products and services excluding the Product only. 

4.6 This Commercial License shall serve as the framework for additional license grants should Bioamber exercise its option to alternative feedstock
pursuant to Section 3 of the Development Agreement, and subject to the terms and conditions specified in Section 3 of the Development Agreement. 
 4.7 Cargill reserves any and all rights under and to Licensed Patents, the CB1 Strain, the Know-How, Cargill Improvements, Cargill Confidential Information, the Licensed Tool Kit, and Joint Improvements
that are not exclusively granted to Bioamber under Section 4.1 of this Commercial License. 
 5. PAYMENTS, ROYALTIES, AND OTHER
CONSIDERATION 
 5.1 In consideration of the rights granted to Bioamber under this Commercial License, including the grants under
Section 4.1 herein, and the rights granted to Bioamber respecting Bioamber Improvements and Joint Improvements as specified in the Development Agreement, Bioamber agrees to the provisions of this Section 5. The Parties acknowledge and
agree that the payments provided in this Section 5 and the obligations for sublicenses under Section 4.2 shall apply without regard to (i) what, if any patents issue respecting Licensed Patents and/or Improvements, the countries in
which such patents issue, the scope of such patents, and whether or not any such patents are necessary or used to make, have made, use, sell or otherwise transfer, offer for sale, export, and/or import a Product and (ii) which party owns the
CB1 Strain, Confidential Information, Licensed Patents, Know-How, and/or Improvements that may be necessary or used to make, have made, use, sell or otherwise transfer, offer for sale, export, and/or import a Product. 

5.2 Bioamber shall pay an up-front fee to Cargill as specified in Section 2.1 of the Development Agreement. Bioamber shall also pay Cargill the
milestone fees as specified in Section 2.3 of the Development Agreement. 
 5.3 Bioamber shall pay Cargill a royalty based on the Net Sale
of the Product during each calendar quarter at the following rate: [***]. Bioamber shall be responsible for making the payments due to Cargill for its own Net Sales and the Net Sales of its sublicensees. 

  
 Cargill
Confidential 
 - 6 - 
 * Confidential treatment requested 

 5.4 Within sixty (60) days of the last day of each Quarter, Bioamber shall submit to Cargill quarterly
reports and royalty payments for each immediately preceding Quarter. Each report shall contain the amount of Net Sales of Product in the preceding Quarter and the total amount of royalties due to Cargill. 

5.5 Bioamber and its sublicensees shall keep complete, true and accurate books and records for the purpose of determining and verifying royalty and other
payment obligations under this Section 5, including those specified in 5.3 and in 5.10. Bioamber agrees to permit its books and records to be examined by an independent auditor not more than once per year, for the purpose of verifying the
payments for Cargill. Bioamber will ensure that sublicensees’ books and records can be examined by an independent auditor on an annual basis on Cargill’s behalf solely to ensure compliance with this Section 5. Bioamber will keep, and
will ensure that its sublicensees keep, these books and records for a minimum of five (5) years following the end of the calendar year to which they pertain. Cargill will pay all costs associated with any audits for this purpose, however in the
event such audit reveals a discrepancy greater than five percent (5%) of the total amount of royalties owed to Cargill, Bioamber agrees to pay for the cost of such audit (including sublicensee audits). 

5.6 Any payments to be made hereunder that remain due and unpaid after a period of sixty (60) calendar days after the date due shall accrue interest
compounded daily, commencing as of the date payment was first past due, at the prime interest rate of Citibank, N.A., in effect on the first day of the calendar month in which the payment first becomes overdue. 

5.7 No part of any amount payable to Cargill by Bioamber may be reduced due to any counterclaim, set off, adjustment or other right. 

5.8 If in any one year period commencing with the Effective Date or the annual anniversary thereof the total royalty payments made by Bioamber to Cargill
is less than $[***] United States dollars, Bioamber shall make additional payment to Cargill to bring the total to $[***] United States dollars within thirty (30) days of the end of that one year period. In the event that Bioamber’s
royalty payments owed in any given year are less than $[***] and Bioamber elects not to pay an additional amount to bring the total to $[***], Cargill’s sole remedy shall be to transform the license it granted to Bioamber under Section 4.1
from an exclusive to a non-exclusive license by written notice to Bioamber. Upon such written notice, (i) Cargill shall have the right to freely license others with respect to the rights granted to Bioamber under Section 4.1 without any
accounting to Bioamber and (ii) Bioamber shall and hereby does grant to Cargill a non-exclusive, worldwide, royalty-free license, with an unlimited right to sublicense, under and to Bioamber Improvements to make, have made, use, sell or
otherwise transfer, offer for sale, export, and/or import succinic acid and salts thereof, including Products. Except as specified in this Section 5.8, such conversion of the exclusive grant by Cargill under Section 4.1 to a non-exclusive
grant shall not otherwise change any term or obligation of this Commercial License, including Bioamber’s payment obligations. For the [***] after the Effective Date or up until [***] following completion of Milestone 3 as specified in the
Development Agreement, whichever occurs first, the amount paid by Bioamber to Cargill for development work under the Development Agreement in any one year period commencing with the Effective Date or the annual anniversary thereof (but not including
any up-front or milestone payments) [***]. 

  
 Cargill
Confidential 
 - 7 - 
 * Confidential treatment requested 

 5.9 In the event that (i) Milestone 3 as specified in the Development agreement is achieved, (ii) the CB1
Strain and fermentation protocols are successfully scaled up, (iii) Bioamber receives any applicable and necessary regulatory approvals to use the CB1 Strain to make and sell Product in any country, and (iv) the economics of using the CB1 Strain
technology is no less favorable than use of Bioamber’s current E. coli strain technology (including OPEX and CAPEX economic considerations), then (a) Bioamber will terminate all of its then existing agreements with licensees licensed to
use technology other than the CB1 Strain to make and sell succinic acid and salts thereof in any and all countries where no regulatory approvals are required or the necessary regulatory approvals for use of CB1 Strain to make and sell the Product
have been obtained, and Bioamber will require such terminated licensees to become sublicensees under this Commercial License, and (b) Bioamber will sublicense only the CB1 Strain technology under this Commercial License to all future Bioamber
licensees for the production of succinic acid and salts thereof in any and all countries where no regulatory approvals are required or the necessary regulatory approvals for use of CB1 Strain to make and sell the Product have been obtained.

 5.10 In addition to the royalties specified in this Section 5, including royalties for sales and other transfers of Product by sublicensees,
Bioamber shall make the following calculation and payment to Cargill. Bioamber shall determine the amount by which the up-front payments, minimum and other cash payments, and royalties that Bioamber receives from any and all sublicensees in
consideration for a sublicense under this Commercial License exceeds the up-front payments, minimum and other cash payments, and royalties, that Bioamber either (i) would receive from such sublicensee under its prior license to Bioamber’s E.
Coli technology for the production of succinic acid (where such sublicensee had such prior license) or (ii) would have received from such sublicensee if such sublicensee would have had a license to Bioamber’s E. Coli technology for
the production of succinic acid under the most favorable license terms existing at the time Bioamber begins switching its licensees to the CB1 Strain technology (where such sublicensee never had such license to Bioamber’s E. Coli
technology). The amount by which the up-front payments, minimum and other cash payments, and royalties that Bioamber receives from any and all sublicensees in consideration for a sublicense under this Commercial License exceeds those from the
licenses to Bioamber’s E. Coli technology as specified in the prior sentence is the “Incremental Value”. Bioamber shall report and pay to Cargill [***] of the Incremental Value within thirty (30) days of Bioamber’s
receipt of the sublicensee payment subject to this payment to Cargill. Cargill shall have the right, through a mutually acceptable third party to audit Bioamber’s license and sublicense agreements to determine the applicable Incremental Value
and determine Bioamber’s payment requirements under this Section 5.10. 

  
 Cargill
Confidential 
 - 8 - 
 * Confidential treatment requested 

 6. INTELLECTUAL PROPERTY 
 6.1 Intellectual property rights, including rights respecting Improvements, are subject to the provisions of Section 5 of the Development Agreement and the terms of this Commercial License.

 7. TERM AND TERMINATION 
 7.1 The
term of this Commercial License shall be from the Effective Date and will continue either (a) until no issued Licensed Patents and no issued patents respecting Improvements remain valid and enforceable, or (b) [***] years after the date of
first commercial sale of Product made in a fully-operational plant (not a sale from a pilot plant), whichever is sooner. Following this initial term (the “Initial Term”), this Commercial License shall automatically renew for successive
[***], and Bioamber shall provide Cargill at least six (6) month notice in the event it decides to terminate this Commercial License prior to any extensions of the Initial Term. Bioamber shall provide written notice to Cargill as to the date of
such first commercial sale and in the event of a dispute the Parties shall resolve such dispute in good faith. Termination of the Development Agreement for any reason, including its end of term, will not terminate this Commercial License.

 7.2 Following the Initial Term, Section 5.3 of this Commercial License shall only apply to the production of sublicenses that continue
to pay licensing revenues to Bioamber (“Eligible Production”). The Eligible Production for the purposes of calculating Section 5.3 of this Commercial License shall be determined each three-month period during such an extension period.
Notwithstanding the foregoing, Bioamber, should it elect to do so, shall continue to pay the annual minimum royalty provided in Section 5.8. 
 7.3 Either Party may terminate this Commercial License at any time for a material breach by the other Party, provided (i) that the Party alleging the breach provides the other with written notice
specifying the breach, and (ii) the breach is not cured within one hundred twenty (120) days. To the extent permitted under applicable law, either Party may terminate this Commercial License in the event of the other Party’s
bankruptcy, insolvency, or the filing of a petition therefore. A Party shall promptly give the other Party notice of its bankruptcy, insolvency, or intent to file a petition therefore, whereupon the other Party may immediately terminate this
Commercial License on written notice to that Party. 
 7.4 Bioamber may terminate this Commercial License upon ninety (90) days written
notice to Cargill. 
 7.5 Termination of this Commercial License for any reason, including the end of its term, terminates all rights and
obligations hereunder, including licenses and sublicenses, except as otherwise specified in this Commercial License. 
 7.6 Upon termination of
this Commercial License by Bioamber pursuant to Section 7.4 or upon Cargill’s termination of this Commercial License pursuant to Section 7.3 as a result of Bioamber’s breach: (i) all of Bioamber’s rights specified in
Sections 5.2.1 and 5.2.2 in the Development Agreement terminate; (ii) Bioamber shall and hereby does assign to Cargill all 

  
 Cargill
Confidential 
 - 9 - 
 * Confidential treatment requested 

 
of its rights, title and interest in and to Bioamber Improvements and Bioamber will have no remaining rights respecting Bioamber Improvements; and (iii) such termination shall have no affect
whatsoever on any license or other intellectual property rights granted from Bioamber to Cargill under the terms of the Commercial License or the Development Agreement. 
 7.7 Expiration or termination of this Commercial License shall not: (a) relieve Bioamber or its sublicensees of their obligation to make payments or fulfill any obligations to Cargill incurred prior
to expiration or termination including quarterly payments for a completed milestone, other royalty and payment obligations, and a pro rata portion of the minimum payment due for the partial year as of the date of termination, or (b) relieve
Cargill of its obligations to Bioamber incurred prior to expiration or termination. 
 7.8 Material breach of this Commercial License by
Bioamber shall include, but not be limited to, the failure of Bioamber to use its best efforts to seek regulatory approval pursuant to Section 2.2 or pay any amounts due under Section 5. 

7.9 Expiration or termination of this Commercial License, however effectuated, shall not release the Parties from their rights and obligations incurred
prior to the expiration or termination of this Commercial License. Except as otherwise provided in this Commercial License, the following provisions survive any expiration or termination of this Commercial License: Sections 3 (Confidential
Information & Transfer of Strains), 4.3, 4.4, 4.5, 5 (Payments, Royalties, and Other Consideration, except for Sections 5.8 (Bioamber’s obligation to pay the $[***] annual minimum payment shall not survive, but Cargill’s license
and rights granted thereunder shall survive), 5.9 and 5.10), 6 (Intellectual Property), 7 (Term and Termination), 8 (Disclaimer of Warranty, Limitation of Liability), 9 (WRF Patents), and 10 (Miscellaneous). 

8. DISCLAIMER OF WARRANTY, LIMITATION OF LIABILITY 
 8.1 CARGILL EXPRESSLY DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE. 

8.2 SUBJECT TO SECTION 8.1, BOTH PARTIES EXPRESSLY DISCLAIM ALL REPRESENTATIONS AND WARRANTIES, EXPRESSED OR IMPLIED, OF NON INFRINGEMENT OF THIRD PARTY
INTELLECTUAL PROPERTY RIGHTS OR OTHER CONFIDENTIAL INFORMATION. 
 8.3 SUBJECT TO SECTIONS 8.1 AND 8.2, IN NO EVENT SHALL EITHER PARTY BE LIABLE
TO THE OTHER PARTY, OR TO THE OTHER PARTY’S OFFICERS, EMPLOYEES OR REPRESENTATIVES, OR TO ANY THIRD PARTY, FOR ANY INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES OF ANY KIND (INCLUDING, BUT NOT LIMITED TO, LOST
BUSINESS, LOST PROFITS, DAMAGE TO GOODWILL OR REPUTATION AND/OR DEGRADATION IN VALUE OF BRANDS, TRADEMARKS, TRADENAMES, SERVICE NAMES OR SERVICE MARKS) WHETHER ARISING OUT OF BREACH OF CONTRACT, WARRANTY, TORT (INCLUDING NEGLIGENCE, FAILURE TO WARN
OR STRICT LIABILITY) OR OTHERWISE. 

  
 Cargill
Confidential 
 - 10 - 
 * Confidential treatment requested 

 8.4 Cargill and its Affiliates shall not be liable to Bioamber, and Bioamber shall indemnify and hold
harmless Cargill and its Afffiliates for any loss, claim, damage, or liability, of whatsoever kind or nature, which may arise from or in connection with Bioamber’s and Bioamber’s sublicensee’s use, handling, or storage of CB1 Strain
and/or Confidential Information received from Cargill. 
 9. WRF PATENTS 
 9.1 As referenced in Section 6 of the Development Agreement, Washington Research Foundation (WRF) is the owner of several patents relating to the expression of polypeptides in yeast (“WRF
Patents”). Bioamber shall be solely responsible for acquiring any licenses or other permissions as described in Section 6 of the Development Agreement from WRF respecting the WRF Patents that may be necessary for Bioamber to exercise its rights
under this Commercial License. Cargill shall have no liability to Bioamber for Bioamber’s acts or failure to act with respect to the WRF Patents, or with respect to any other third party that may have intellectual property rights that may be
necessary for Bioamber to exercise its rights under this Commercial License. 
 10. MISCELLANEOUS 

10.1 This Commercial License is personal to the parties hereto and shall not be assigned by either Party without the prior written consent of the other
Party. Notwithstanding the foregoing, no assignment of this Commercial License shall be made effective unless (i) any breach or default of the intended assignor is cured by either the intended assignor or the intended assignee, or (ii) the
intended assignee can give reasonable assurances of its ability to comply with the terms and conditions of this Commercial License, and to fulfill its intent. This Commercial License shall be binding upon and shall inure to the benefit of the
Parties and their permitted successors and assigns. 
 10.2 All notices and reports respecting this Commercial License shall be sent via
facsimile, mail, or electronically to the appropriate address of the Party as given below. If either Party wishes to change its address for notification, it shall promptly notify the other Party in writing of such change of address. 

  
 Cargill
Confidential 
 - 11 - 
 * Confidential treatment requested 

			
	 If to Cargill:
	  	Pirkko Suominen
		  	15285 Minnetonka Blvd.
		  	Minnetonka, MN 55345
		  	Phone: [***]
		  	Fax: 952-742-0540
		  	[***]
		
	 with a copy to:
	  	Cargill Incorporated
		  	 Corn Milling Intellectual Property Atty.

		  	 15407 McGinty Road West

		  	 Mailstop 24

		  	 Wayzata, MN 55391-2399

		
	 If to Bioamber:
	  	Laurent Bernier
		  	Bioamber SAS
		  	1250 Rene-Levesque West
		  	Suite 4110
		  	Montreal, Quebec
		  	Canada
		  	H3B4W8
		  	Phone: 514-844-8000
		  	Fax: 514-844-1414
		  	[***]
		
	 with a copy to:
	  	Thomas Desbiens, Esq
		  	Boivin Desbiens Senecal, g.p.
		  	2000-2000 McGill College Avenue
		  	Montreal, Quebec
		  	Canada
		  	H3A 3H3
		  	Phone: 514-844-5468
		  	Fax: 514-844-5836
		  	[***]

 10.3 Nothing contained herein shall limit the right of any Party to seek specific performance, injunctive relief or other
non-monetary remedies in any court of competent jurisdiction. 
 10.4 If any provision or covenant, or any part thereof, of this Commercial
License should be held by any court of competent jurisdiction to be invalid, illegal or unenforceable, either in whole or in part, such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of the
remaining provisions or covenants, or any part thereof, of this Commercial License, all of which shall remain in full force and effect. 
 10.5
This Commercial License shall be governed, interpreted, and construed in accordance with the laws of Minnesota without regard to the principles of conflicts of laws. 
 10.7 This Commercial License and the Development Agreement constitutes the entire agreement between the Parties with respect to the subject matter hereto, and no other representations, guarantees,
covenants, or agreements shall be binding or affect any provisions hereof. This Commercial License may be modified only in a written amendment signed by both Parties hereto. In the event that the terms of this Commercial License conflict with the
Terms of the Development Agreement, this Commercial License shall control. Provisions of the Development Agreement which are referenced by this Commercial License shall survive termination or end of term of the Development Agreement for the purpose
referenced in this Commercial License. 

  
 Cargill
Confidential 
 - 12 - 
 * Confidential treatment requested 

 IN WITNESS WHEREOF, the Parties hereto have executed this Commercial License the day, month, and year first
above written. 
  

									
	Cargill, Inc.	 		 	Bioamber S.A.S.
					
	By:	 	/s/ Jack Stalock	 		 	By:	 	/s/ J.F. Huc
	Name:	 	Jack Stalock	 		 	Name:	 	J.F. Huc
	Title:	 	VP BioTDC	 		 	Title:	 	Director General
	Date:	 	4/16/10	 		 	Date:	 	April 15 2010

  
 Cargill
Confidential 
 - 13 - 
 * Confidential treatment requested 

 EXHIBIT X 
 Affiliates 
 The following shareholders of Bioamber, until such time that they cease to be
a shareholder of Bioamber, at which point they will no longer be considered Affiliates: 
 DNP Green Technology 

Agrorecherches et Developpement (ARD) 

  
 Cargill
Confidential 
 - 14 - 
 * Confidential treatment requested 

 EXHIBIT Y 
 Prohibited Geographies 
 [***] 

  
 Cargill
Confidential 
 - 15 - 
 * Confidential treatment requested 

 Exhibit Z 
 Cargill’s Guiding Principles 
 Guiding Principles 

 

	 	•	 	 Cargill will comply with the laws of all countries to which it is subject. 

 

	 	•	 	 Cargill will not knowingly assist any third party to violate any law of any country, by creating false documents or by any other means.

  

	 	•	 	 Cargill will not pay or receive bribes or participate in any other unethical, fraudulent, or corrupt practice. 

 

	 	•	 	 Cargill will always honor all business obligations that it undertakes with absolute integrity. 

 

	 	•	 	 Cargill will keep its business records in a manner that accurately reflects the true nature of its business transactions. 

 

	 	•	 	 Cargill managers and supervisors will be responsible that employees, consultants and contract workers under their supervision are familiar with
applicable laws and company policies and comply with them. Further, they will be responsible for preventing, detecting, and reporting any violations of law of Cargill policies. 

 

	 	•	 	 Cargill employees will not become involved in situations that create a conflict of interest between the company and the employee.

  

	 	•	 	 Every year, all Cargill employees sign an agreement to live these principles. 

Compliance Policy on Intellectual Property 
 [*** 2 pages omitted.] 

  
 Cargill
Confidential 
 - 16 - 
 * Confidential treatment requested 

 AMENDMENTS TO COMMERCIAL LICENSE AGREEMENT AND DEVELOPMENT AGREEMENT 

WHEREAS, Cargill, Incorporated (“Cargill”) and BioAmber S.A.S. (“Bioamber”) entered into a
Development Agreement having an Effective Date of April 15th, 2010, as amended on July 5th, 2011 (the “Development Agreement”); 
 WHEREAS, Cargill and Bioamber
entered into a Commercial License Agreement having an Effective Date of April 15, 2010 (the “Commercial License”); 
 WHEREAS, Bioamber now desires to amend the Development Agreement to allow Bioamber to fund a research project being conducted by the Biotechnology Research Institute (“BRI”), which involves the
molecular re-engineering of a Methylotroph owned by BRI and the development of a lab scale fermentation design for using the re-engineered methylotroph to make succinic acid or salts thereof from a methanol feedstock (the “BRI Project”).
The BRI Project will be co-funded by funds available from the Canadian National Research Council; 
 WHEREAS, Bioamber further
desires to scale-up the production of succinic acid using a Corynebacteria biocatalyst (MCC-17) available from Mitsubishi Chemical Corporation (“MCC”) and to possibly produce succinic acid or salts using MCC-17 as an alternative to the E.
coli BioAmber has licensed from the DOE at: (1) Bioamber’s existing demonstration-scale succinic acid production facility located at Pomacle, France; and (2) a succinic acid production facility located at Sarnia, Ontario Canada having a maximum
production capacity of 35,000 metric tons of succinic acid per year (the “Sarnia Plant”). Together these scale-up projects will be referred to as the “Scale-up and Production Project”; 

WHEREAS, Cargill is willing to allow Bioamber to fund the BRI Project and to conduct the Scale-up and Production Project, subject to the
following terms and conditions. Now therefore the Parties agree: 
 Amendment To the Development Agreement 

A. Section 13.9 of the Development Agreement is amended to add the following at the end of the Section: 

“Notwithstanding the above, Bioamber may fund the BRI Project up until the Methylotroph (or re-engineered Methylotroph) demonstrates
the ability to produce succinic acid (or salts thereof) from any feedstock at a concentration of [***] grams/liter succinic acid (or salts thereof). Within thirty (30) days of the Methylotroph (or re-engineered Methylotroph) demonstrating such
production levels of succinic acid, Bioamber will cease any further funding and/or other support for the BRI Project. Further Bioamber will require that any unexpended funds received from Bioamber be utilized for a project other than the BRI
Project. 
 B. New Section 13.10 is added to the Development Agreement as set forth below: 

“13.10 Notwithstanding the provisions of section 13.9, Bioamber may conduct the Scale-up and Production Project, subject to Bioamber hereby agreeing
to convert the demonstration-scale Pomacle France succinic acid production facility and the Sarnia Plant to solely utilize CB1 as the biocatalyst for the production of succinic acid (and/or salts thereof). This conversion will be carried out
according to the provisions of Section 5.9 of the Commercial License, it being understood that all economic obligations of item (iv) above will be relative to the E. coli strain technology, not the Mitsubishi strain technology. In order to enable
such conversion, Bioamber will put in place agreements with the owners/operators of the Sarnia Plant that will enable Bioamber to require such conversion of the Sarnia Plant to solely use CB1 for the manufacture of succinic acid as described
above.” 
 Amendment To the Commercial License 
 A. Section 5.9 of the Commercial License is amended to add the following at the end of the Section: 
 “Bioamber shall use best efforts to obtain regulatory approvals for the use of the CB1 Strain in all countries where Bioamber and/or a Bioamber licensee are using any strain other than the CB1 strain
for the production of succinic acid and/or salts thereof. Additionally, Bioamber shall use best efforts to scale up the CB1 Strain and fermentation protocols utilizing the CB1 Strain.” 
 Nothing in these amendments will reduce Bioamber’s obligations to replace MCC-17 and Bioamber’s current E. coli strain with CB1 in all the existing and future succinic acid production facilities
of Bioamber and Bioamber licensees, according to the provisions of Section 5.9 of the Commercial License. 

  
 * Confidential
treatment requested 

 
			
	CARGILL, INCORPORATED
		
	By:	 	 /s/ Pirkko Suominen

		 	 Name: Pirkko Suominen

		 	 Title: Director, Bio Technology Development Center,
Minneapolis

	 Date:
	 	 10/19/2011

	
	BIOAMBER, SAS
		
	By:	 	 /s/ Jean-François Huc

		 	 Name: Jean-François Huc

		 	 Title: President

	 Date:
	 	 October 15, 2011

  
 * Confidential
treatment requested

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}]]